17,261 trials
Breast Cancer
Primary: Change in Percent Expression of Ki67 Measured by Immunohistochemistry (IHC) — -3.6; -5.1; -4.2 Change in percentage expression of ki 67
Macular Oedema · Retinitis Pigmentosa
Primary: Mean Central Macular Thickness (CMT) on Spectral Domain OCT (SDOCT) at 12 Months — 413.4 Microns
Covid19
Primary: Red Blood Cell to Membrane (RBC:M) Ratio — 0.39; 0.51 ratio (RBC:M)
Atrial Fibrillation
Primary: Percentage of Participants Who Converted From Atrial Fibrillation (AF) Within 90 Minutes From Start of Infusion and Subsequently Had no AF Recurrence Within 1 Minute of…
Stage IV Non-Small Cell Lung Cancer
Primary: Number of Patients With Each Response as Measured by RECIST 1.1 — 0; 4; 2; 5 Participants
Familial Cold Autoinflammatory Syndrome
Primary: Ratio of Fold Change From Pre-challenge to the Highest Post-challenge Value of White Cell Count (WCC) Between Treatment and Screening Period — 0.82 ratio of fold change
Non-Small Cell Lung Cancer · Epigenetic Therapy
Primary: Objective Response — 4; 1; 5; 3 Participants
Cervical Intraepithelial Neoplasia · Cervical Dysplasia
Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043
Hepatitis B
Primary: Treatment Arm 1 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment — 9 Percentage of Participants
OSA · Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index (AHI) — 17.1; 32.7; 26; 23.6 events/hour of sleep
Plasmodium Falciparum Infection · Malaria
Primary: Participants With Local Adverse Events (AEs) — 1; 0; 0; 2 Participants
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Progression Free Survival (PFS) — 3; 6; 0; 8 Participants
Esophageal Cancer · GastroEsophageal Cancer
Primary: Pathologic Complete Response (pCR) Rate (%) Overall — 37.9 percentage of participants
HIV
Primary: Area Under the Plasma Concentration-time Curve From Time of Administration up to 24 Hours Postdose (AUC[0-24h]) of Rilpivirine 12.5 mg (for <20 kg Group) — 4116; 4646…
Colorectal Cancer · Pancreatic Cancer · Lung Cancer
Primary: Pathologic Response Based on Tumor Regression Grading in Cohort A Patients — 1 Participants